全文获取类型
收费全文 | 20172篇 |
免费 | 1325篇 |
国内免费 | 471篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 462篇 |
妇产科学 | 150篇 |
基础医学 | 3073篇 |
口腔科学 | 117篇 |
临床医学 | 1227篇 |
内科学 | 3718篇 |
皮肤病学 | 112篇 |
神经病学 | 88篇 |
特种医学 | 160篇 |
外国民族医学 | 3篇 |
外科学 | 468篇 |
综合类 | 2294篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 7548篇 |
眼科学 | 34篇 |
药学 | 1373篇 |
6篇 | |
中国医学 | 152篇 |
肿瘤学 | 946篇 |
出版年
2024年 | 12篇 |
2023年 | 546篇 |
2022年 | 824篇 |
2021年 | 963篇 |
2020年 | 786篇 |
2019年 | 749篇 |
2018年 | 764篇 |
2017年 | 694篇 |
2016年 | 713篇 |
2015年 | 802篇 |
2014年 | 1080篇 |
2013年 | 1438篇 |
2012年 | 1092篇 |
2011年 | 1342篇 |
2010年 | 1081篇 |
2009年 | 1108篇 |
2008年 | 769篇 |
2007年 | 978篇 |
2006年 | 873篇 |
2005年 | 774篇 |
2004年 | 652篇 |
2003年 | 594篇 |
2002年 | 482篇 |
2001年 | 404篇 |
2000年 | 360篇 |
1999年 | 323篇 |
1998年 | 224篇 |
1997年 | 234篇 |
1996年 | 160篇 |
1995年 | 144篇 |
1994年 | 147篇 |
1993年 | 105篇 |
1992年 | 100篇 |
1991年 | 100篇 |
1990年 | 94篇 |
1989年 | 91篇 |
1988年 | 84篇 |
1987年 | 51篇 |
1986年 | 46篇 |
1985年 | 62篇 |
1984年 | 31篇 |
1983年 | 18篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 10篇 |
1979年 | 7篇 |
1978年 | 9篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1974年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
112.
Chou TH Wang S Sakhatskyy PV Mboudjeka I Mboudoudjeck I Lawrence JM Huang S Coley S Yang B Li J Zhu Q Lu S 《Virology》2005,334(1):134-143
Inactivated severe acute respiratory syndrome-associated coronavirus (SARS-CoV) has been tested as a candidate vaccine against the re-emergence of SARS. In order to understand the efficacy and safety of this approach, it is important to know the antibody specificities generated with inactivated SARS-CoV. In the current study, a panel of twelve monoclonal antibodies (mAbs) was established by immunizing Balb/c mice with the inactivated BJ01 strain of SARS-CoV isolated from the lung tissue of a SARS-infected Chinese patient. These mAbs could recognize SARS-CoV-infected cells by immunofluorescence analysis (IFA). Seven of them were mapped to the specific segments of recombinant spike (S) protein: six on S1 subunit (aa 12-798) and one on S2 subunit (aa 797-1192). High neutralizing titers against SARS-CoV were detected with two mAbs (1A5 and 2C5) targeting at a subdomain of S protein (aa 310-535), consistent with the previous report that this segment of S protein contains the major neutralizing domain. Some of these S-specific mAbs were able to recognize cleaved products of S protein in SARS-CoV-infected Vero E6 cells. None of the remaining five mAbs could recognize either of the recombinant S, N, M, or E antigens by ELISA. This study demonstrated that the inactivated SARS-CoV was able to preserve the immunogenicity of S protein including its major neutralizing domain. The relative ease with which these mAbs were generated against SARS-CoV virions further supports that subunit vaccination with S constructs may also be able to protect animals and perhaps humans. It is somewhat unexpected that no N-specific mAbs were identified albeit anti-N IgG was easily identified in SARS-CoV-infected patients. The availability of this panel of mAbs also provided potentially useful agents with applications in therapy, diagnosis, and basic research of SARS-CoV. 相似文献
113.
Restriction endonuclease analysis of varicella-zoster vaccine virus and wild-type DNAs 总被引:9,自引:0,他引:9
The DNA from several clinical isolates of varicella-zoster virus (VZV) were compared with the DNA from the vaccine strain VZV using three restriction endonucleases: BamHI, BgII, and HpaI. When electrophoresed through an agarose gel, the vaccine DNA digestion pattern was significantly different from the digestion patterns of the wild-type DNAs. Variations in the digestion pattern of the separate clinical isolates were also observed. 相似文献
114.
Comparison of the COBAS TaqMan HBV test with the COBAS Amplicor monitor test for measurement of hepatitis B virus DNA in serum 总被引:3,自引:0,他引:3
Quantitation of low hepatitis B virus (HBV) DNA levels in patients with chronic hepatitis B is important for monitoring natural history of disease and treatment efficacy. This study aimed to compare the quantitation range and analytical sensitivity of the newly developed COBAS TaqMan HBV test (TaqMan test) with the COBAS Amplicor HBV Monitor Test (Amplicor test), using the Eurohep HBV reference plasma and serum samples from patients. Serial dilutions (2.7x10(1)-2.7x10(8) copies/ml) of the Eurohep HBV reference plasma and 50 serum samples from chronic hepatitis B patients were tested by both assays. The TaqMan test could detect seven (2.7x10(2)-2.7x10(8) copies/ml) of eight dilutions of the reference plasma, while the Amplicor test could only detect three of them (2.7x10(3)-2.7x10(5) copies/ml). The HBV DNA values measured by the TaqMan test correlated very well with the theoretical Eurohep standard values (r=0.998, P<0.001). There were good correlations between the HBV DNA levels measured by the two assays on both the Eurohep reference plasma (r=0.993, P<0.001) and serum samples from patients (r=0.904, P<0.001). Compared to the Amplicor test, the TaqMan test had a higher sensitivity (50 vs. 300 copies/ml), shorter assay time (6 vs. 10 hr), and wider dynamic range (8 vs. 3 logs), and was more cost-effective in a clinical setting. These data indicate that the TaqMan test is an excellent tool for HBV DNA quantitation. 相似文献
115.
Jolivet-Reynaud C Lésenéchal M O'Donnell B Becquart L Foussadier A Forge F Battail-Poirot N Lacoux X Carman W Jolivet M 《Journal of medical virology》2001,65(2):241-249
Small hepatitis B surface antigen (HBsAg) is considered to be the best marker for the diagnosis of Hepatitis B virus infection. However, HBsAg variants with mutations within the "a" determinant may be poorly or not detected by diagnostic assays. Three anti-HBsAg monoclonal antibodies (6H6B6, 27E7F10, and 2G2G10), directed against conformational epitopes, were tested for their ability to detect the wild-type HBsAg as well as variant forms and their respective epitopes were localised on the HBsAg sequence by using the phage-displayed peptide library technology. Whereas 6H6B6 did not detect mutations T123N, S143L, D144A and G145R, 27E7F10 binding was affected by mutations P120T and G145R. In contrast, 2G2G10 reacted strongly with all tested variants including variant with the G145R mutation. Part of the 6H6B6 epitope was located in the major hydrophilic region (MHR) at residues 101-105, the 27E7F10 epitope (residues 214-219) was located near the C-terminal end of the antigen and the 2G2G10 epitope at residues 199-208, within the theoretical fourth transmembrane helix. The 2G2G10 epitope localisation brings information about the HBsAg structure and the validity of established topological models. Finally, 2G2G10 is a valuable tool for HBsAg variant detection that is used as capture phase in a new bioMérieux diagnostic assay, which is currently in development. 相似文献
116.
脂质体转染AFP基因构建树突状细胞肝癌瘤苗及体外活性检测 总被引:5,自引:0,他引:5
目的:探讨以AFP为靶点,构建AFP-DC肝癌瘤苗及其抗肝癌免疫治疗的可能性。方法:应用脂质体将AFP基因转染体外培养的未成熟 BMDC,构建 AFP-DC肝癌瘤苗,以流式细胞术、Western blot、3H-TdR法和 MTT法等检测其免疫活性。结果:AFP-DC瘤苗不仅能产生和分泌AFP,而且能上调自身的B7分子和MHC分子,明显刺激T细胞增殖及提高CTL的杀伤作用。结论:提示肝癌相关基因AFP可作为抗肝癌基因治疗的切入点。 相似文献
117.
Newman JT Surman SR Riggs JM Hansen CT Collins PL Murphy BR Skiadopoulos MH 《Virus genes》2002,24(1):77-92
A complete consensus sequence was determined for the genomic RNA of human parainfluenza virus type 1 (HPIV1) strain Washington/20993/1964 (HPIV1 WASH/64), a clinical isolate that previously was shown to be virulent in adults. The sequence exhibited a high degree of relatedness to both Sendai virus, a PIV1 virus recovered from mice, and human PIV3 (HPIV3) with regard to cis-acting regulatory regions and protein-coding sequences. This consensus sequence was used to generate a full-length antigenomic cDNA and to recover a recombinant wild-type HPIV1 (rHPIV1). Interestingly, the rHPIV1 could be rescued from full-length antigenomic rHPIV1 cDNA using HPIV3 support plasmids, HPIV1 support plasmids, or a mixture thereof. The replication of rHPIV1 in vitro and in the respiratory tract of hamsters was similar to that of its biologically derived parent virus. The similar biological properties of rHPIV1 and HPIV1 WASH/64 in vitro and in vivo, together with the previous demonstration of the virulence of this specific isolate in humans, authenticates the rHPIV1 sequence as that of a wild-type virus. This rHPIV1 can now be used to study the biological properties of HPIV1 and as a substrate to introduce attenuating mutations for the generation of live-attenuated HPIV1 vaccine candidates.An erratum to this article can be found at 相似文献
118.
经丝裂霉素C体外处理后,将IL-6基因转染的、高分泌的IL-6的B16黑色素瘤细胞制成瘤苗。结果发现,体内注射IL-6基因转染的瘤苗后,小鼠脾脏CTL活性、NK活性及IL-2诱导的LAK活性显著升高。经IL-6基因转染瘤苗体内治疗后,荷瘤小鼠的皮下肿瘤生长显著减慢、肺转移结节数显著降低、存活期显著延长,若同时合用低剂量IL-2,则上述治疗效果更好。可见IL-6基因转染的瘤苗能有效地通过诱导机体抗肿瘤免疫功能而发挥抗肿瘤作用,与低剂量IL-2合用后,IL-6基因转染的瘤苗的抗肿瘤效果更佳。 相似文献
119.
Wolf Szmuness Cladd E. Stevens Edward J. Harley Edith A. Zang Patricia E. Taylor Harvey J. Alter The Dialysis Vaccine Trial Group 《Journal of medical virology》1981,8(2):123-129
Three hundred thirty-six medical personnel from hemodialysis centers were treated with three doses, 20 μg each, of the Merck hepatitis B vaccine (at 0, 1, and 6 months). Within 1 month after the first injection, 41% converted to anti-HBs positivity; after the second injection the conversion rate rose to 80–90%; and after the booster, to 96–98%. The later rate remained unchanged during the 18-month follow-up period. Only 2.8% of those vaccinated did not respond to the vaccine. The patterns of immune responses to 20-μg doses were found to be exactly the same as to 40-μg doses. It is suggested that reduced doses of vaccine should be as efficacious as the larger ones. 相似文献
120.
Manabu Daikoku Keisuke Nakata Keisuke Hamasaki Akio Ido Kazuhiko Nakao Yuji Kato Michiaki Koga Michitami Yano Shigenobu Nagataki 《Journal of medical virology》1995,47(2):184-188
Hepatitis B virus (HBV), with a G-to-A point mutation at nucleotide 83 in the precore region (mutant HBV83), accounts for most cases of hepatitis B e antigen (HBeAg)-defective HBV. However, it is still not clear how mutant HBV83 is associated with HBe seroconversion. Twenty-six HBeAgpositive patients with chronic hepatitis B who received oral prednisolone (30 mg/day) for 3 weeks were studied to clarify the prevalence of mutant HBV83 during the treatment using polymerase chain reaction with a restriction fragment length polymorphism assay. Twelve (46%) patients seroconverted to anti-HBe 1 year after treatment, whereas 14 (54%) did not. The proportion of mutant HBV83 to whole HBV remained unchanged in both groups during an acute exacerbation induced by withdrawal of corticosteroids. Among 12 anti-HBe-0seroconverted patients, five (56%) of nine patients with only wild-type HBV at baseline developed detectable levels of mutant HBV83 while all three patients with a mixed viral population of wild-type HBV and mu tant HBV83 at baseline developed a higher pro portion of mutant HBV83 one year after treat ment. In contrast, these changes were observed in only one (14%) of seven who failed to seroconvert. The results indicate that a flare-up of hepa titis precedes emergence or selection of mutant HBV83, followed by HBe seroconversion in patients with chronic hepatitis B. © 1995 WiIey-Liss, Inc. 相似文献